ReviewFrontiers in cardiovascular medicine2025
Cardiac disease mechanobiology: advances using hiPSC-CMs.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Stage-associated differences in injury and stress responses of hiPSC-derived cardiomyocytes under macrophage-derived inflammatory stimulation.Translational pediatrics · 2026Article
- Clinical translation and engineering challenges of soft robotic cardiac sleeves for heart failure.Nature communications · 2026Review
- Restoring anisotropy after myocardial injury: strategies to align transplanted human induced pluripotent stem-cell-derived cardiomyocytes.Experimental & molecular medicine · 2026Review
- Magnetic torque-mediated early asymmetric mechanical stimulation directs structural and functional maturation in human cardiac organoids.Scientific reports · 2026Article
- Engineering a Quantitative Organ-on-a-Chip Platform for Myogenic Mechanobiology.Bioengineering (Basel, Switzerland) · 2026Article
- The Emerging Role of Mechanobiology in Connecting Metabolic and Cardiovascular Diseases: From Fundamentals to Future Therapies.Biomedicines · 2026Review
- Monocytes and neutrophils promote cardiac fibroblast pro-fibrotic phenotypes through IL-6 and MIF.Frontiers in cell and developmental biology · 2026Article
- PCSK9 inhibition alleviates sepsis-induced myocardial dysfunction by facilitating PINK1/parkin-associated mitophagy.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide. Despite advances in diagnosis and treatment, there is a critical need for sophisticated models that accurately reflect human cardiovascular pathophysiology. This mini review explores recent advancements in cardiac microenvironment engineering for modeling cardiac mechanobiology and investigating genetic and acquired cardiac diseases. Cardiac function relies heavily on mechanical cues, with integrin- and cadherin-based adhesion complexes mediating mechanosensitive signaling that drives disease progression. However, studying these processes in humans remains challenging. Although animal models have been indispensable, they often fail to recapitulate human-specific cardiac features. Human-induced pluripotent stem cells (hiPSCs) have been transformative, enabling patient-specific modeling and the identification of disease-specific phenotypes that are challenging to replicate in traditional animal models. Despite their promise, hiPSC-CMs are constrained by their immature phenotype and heterogeneity, which limits their efficacy in modeling adult cardiac physiology. Emerging
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.